Association of LncRNA‐GAS5 gene polymorphisms and PBMC LncRNA‐GAS5 level with risk of systemic lupus erythematosus in Chinese population

• Published in: Journal of cellular and molecular medicine Vol. 25; no. 7; pp. 3548 - 3559
• Main Authors: Liu, Chun‐Hong, Lu, Yu‐Lan, Huang, Hua‐Tuo, Wang, Chun‐Fang, Luo, Hong‐Cheng, Wei, Gui‐Jiang, Lei, Ming, Tan, Tan, Wang, Yan, Huang, Yan‐Yun, Wei, Ye‐Sheng, Lan, Yan
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.04.2021; John Wiley and Sons Inc
• Subjects: Age; Alleles; Antibodies; Autoimmune diseases; Binding sites; Bioinformatics; Biomarkers; Deoxyribonucleic acid; DNA; Enzyme-linked immunosorbent assay; Gender; Gene deletion; Gene expression; Gene polymorphism; Genotyping; Haplotypes; Hospitals; Insertion; Kinases; LncRNA‐GAS5; Lupus; MicroRNAs; miR‐21; Non-coding RNA; Original; Pathogenesis; Peripheral blood mononuclear cells; Population growth; PTEN; PTEN protein; Rheumatoid arthritis; Signal transduction; single nucleotide polymorphism; Software; Systemic lupus erythematosus; PTEN; LncRNA-GAS5; systemic lupus erythematosus; miR-21; single nucleotide polymorphism
• ISSN: 1582-1838; 1582-4934
• DOI: 10.1111/jcmm.16438

Growth arrest‐specific 5 (GAS5) is a kind of long non‐coding RNAs (lncRNAs). Previous studies showed that down‐regulation of LncRNA‐GAS5 was involved in the development of systemic lupus erythematosus (SLE). However, the regulatory mechanism of down‐expressed LncRNA‐GAS5 in SLE remains obscure. In this study, we aimed to investigate the association of LncRNA‐GAS5 polymorphism with SLE risk. And further explore how LncRNA‐GAS5 is involved in the occurrence of SLE. Here, we evaluated the relationship between the risk for the development of SLE and the 5‐base pair (AGGCA/‐) insertion/deletion (I/D) polymorphism (rs145204276) in the LncRNA‐GAS5 promoter region. A custom 36‐Plex SNPscan kit was used for genotyping the LncRNA‐GAS5 polymorphisms. The LncRNA‐GAS5 and miR‐21 target prediction was performed using bioinformatics software. Enzyme‐linked immunosorbent assay (ELISA) and quantitative real‐time PCR (qRT‐PCR) were performed to assess GAS5 and miR‐21 mRNA expression and PTEN protein expression. The results revealed that rs145204276 resulted in a decreased risk of SLE (DD genotypes vs II genotypes: adjusted OR = 0.538, 95% CI, 0.30‐0.97, P = .039; ID genotypes vs II genotypes: adjusted OR = 0.641, 95% CI, 0.46‐0.89, P = .007; ID/DD genotypes vs II genotypes: adjusted OR = 0.621, 95% CI, 0.46‐0.84, P = .002; D alleles vs I alleles: adjusted OR = 0.680, 95% CI, 0.53‐0.87, P = .002). A reduced incidence of renal disorders in SLE was found to be related to ID/DD genotypes and D alleles (ID/DD genotypes vs II genotypes: OR = 0.57, 95% CI, 0.36‐0.92, P = .020; D alleles vs I alleles: OR = 0.63, 95% CI, 0.43‐0.93, P = .019). However, no significant association of rs2235095, rs6790, rs2067079 and rs1951625 polymorphisms with SLE risk was observed (P > .05). Additionally, haplotype analysis showed that a decreased SLE risk resulted from the A‐A‐C‐G‐D haplotype (OR = 0.67, 95% CI, 0.49‐0.91, P = .010). Also, patients in the SLE group showed a down‐regulated expression of LncRNA‐GAS5 and PTEN than the healthy volunteers; however, patients with rs145204276 ID/DD genotypes showed up‐regulated expression of LncRNA‐GAS5 and PTEN compared with patients carrying the II genotype. Furthermore, the miR‐21 levels were considerably up‐regulated in the SLE group than the healthy volunteers, and patients with rs145204276 ID/DD genotype had lower miR‐21 levels than the ones with the II genotype. Thus, we found that the LncRNA‐GAS5/miR‐21/PTEN signalling pathway was involved in the development of SLE, where LncRNA‐GAS5 acted as an miR‐21 target, and miR‐21 regulated the expression of PTEN. These findings indicated that the rs145204276 ID/DD genotypes in the LncRNA‐GAS5 gene promoter region may be protected against SLE by up‐regulating the expression of LncRNA‐GAS5, which consecutively regulated miR‐21 and PTEN levels.